group
streptococcu
ga
bacteri
pathogen
respons
wide
spectrum
clinic
manifest
mild
common
infect
includ
pharyng
impetigo
moreseri
infect
streptococc
toxic
shock
syndrom
necrot
fasciiti
sepsi
rel
rare
yet
lifethreaten
condit
poststreptococc
sequela
manifest
follow
repeat
mild
infect
form
acut
rheumat
fever
arf
rheumat
heart
diseas
rhd
global
burden
streptococc
diseas
long
neglect
despit
respons
estim
death
annual
recent
advocaci
effort
highlight
urgent
need
develop
vaccin
prevent
gasrel
infect
proteinbas
vaccin
consid
strong
candid
despit
concern
insuffici
serotyp
coverag
nterminalbas
vaccin
associ
protein
gener
crossreact
antibodi
link
arf
rhd
hand
nonm
proteinbas
vaccin
emerg
altern
candid
overcom
concern
regardless
choic
ga
antigen
use
vaccin
candid
choic
adjuv
signific
element
final
vaccin
formul
gener
overlook
aluminum
salt
alum
repres
common
adjuv
use
test
ga
vaccin
candid
mprotein
base
vaccin
alum
proven
effect
gener
opson
antibodi
associ
protect
infect
anim
model
howev
less
known
potenti
correl
protect
nonm
proteinbas
vaccin
role
differ
adjuv
may
play
protect
afford
vaccin
research
focus
develop
vaccin
combin
ga
protein
antigen
arginin
deiminas
adi
peptidas
scpa
streptolysin
slo
proteas
spycep
trigger
factor
tf
previous
test
formul
alum
murin
nonhuman
primat
nhp
model
infect
variou
result
immun
decreas
sever
clinic
sign
reduc
colon
nhp
pharyng
model
infect
provid
protect
murin
superfici
skin
infect
model
formul
fail
protect
murin
invas
model
diseas
studi
take
advantag
opportun
present
find
examin
protect
capac
formul
panel
differ
adjuv
tabl
use
invas
ga
diseas
model
level
protect
lethal
challeng
rang
surviv
among
differ
formul
character
protect
immun
respons
elicit
formul
smq
adjuv
compar
nonprotect
respons
elicit
protect
respons
elicit
gold
standard
homolog
protein
formul
alum
group
human
plasminogen
mice
immun
formul
alum
swe
lq
lmq
smq
adjuv
tabl
negativecontrol
group
immun
phosphatebuff
salin
pb
plu
correspond
adjuv
one
primari
two
booster
immun
deliv
via
intramuscular
inject
thigh
muscl
serum
sampl
day
use
measur
antigenspecif
antibodi
protein
contain
antigenspecif
total
igg
endpoint
titer
antigen
adi
scpa
slo
spycep
tf
adjuv
vaccin
fig
blue
circl
significantli
higher
titer
seen
correspond
neg
control
fig
black
circl
immun
use
posit
control
experi
fig
show
igg
titer
one
repres
experi
day
mice
infect
subcutan
ga
strain
dose
rang
cfu
cfu
mice
monitor
day
postinfect
anim
show
sign
diseas
pain
distress
human
euthan
classifi
succumb
infect
shown
previou
studi
immun
provid
significantli
greater
protect
treatment
pbsalum
fig
mice
immun
show
protect
compar
mice
immun
adjuv
alon
mirror
situat
fig
mice
immun
formul
show
surviv
lethal
challeng
although
result
signific
compar
surviv
rate
seen
mice
immun
alon
fig
formul
lq
lmq
smq
adjuv
show
significantli
higher
level
surviv
protect
respect
observ
control
treat
adjuv
alon
fig
mice
immun
consist
protect
infect
surviv
across
experi
fig
character
immun
respons
induc
formul
provid
highest
protect
invas
lethal
challeng
compar
immun
respons
induc
four
mice
per
group
immun
naiv
mice
use
neg
control
day
follow
one
primari
immun
two
booster
immun
anim
human
euthan
obtain
blood
spleen
analys
level
antigenspecif
igg
subclass
measur
serum
sampl
serum
titer
adi
significantli
higher
mice
immun
fig
hand
antiadi
titer
significantli
higher
mice
mice
titer
antiadi
compar
two
group
antiscpa
antitf
titer
significantli
higher
mice
receiv
formul
receiv
titer
antigen
compar
fig
titer
slo
significantli
higher
mice
treat
wherea
titer
equival
two
formul
fig
antispycep
antibodi
titer
significantli
differ
formul
signific
differ
observ
titer
group
titer
undetect
group
fig
igg
subclass
respons
follow
immun
character
high
titer
follow
titer
low
titer
antibodi
fig
ratio
calcul
antigen
protein
formul
fig
ratio
closer
observ
indic
balanc
respons
fig
hand
higher
ratio
obtain
antigen
formul
alum
suggest
antibodi
respons
fig
bind
immun
serum
live
ga
assess
use
flow
cytometri
sera
mice
show
significantli
higher
fluoresc
sera
naiv
mice
express
calcul
x
valu
fig
function
antibodi
sera
evalu
use
vitro
opsonophagocyt
kill
assay
immun
sera
abl
promot
opsonophagocyt
kill
ga
fig
opson
index
significantli
higher
measur
naiv
mice
final
investig
cytokin
secret
splenocyt
immun
mice
follow
antigen
stimul
mice
splenocyt
stimul
antigen
mice
splenocyt
stimul
protein
naiv
splenocyt
stimul
protein
follow
h
stimul
cultur
supernat
use
quantifi
panel
cytokin
gamma
interferon
tumor
necrosi
factor
alpha
respons
character
secret
fig
splenocyt
mice
secret
low
level
fig
splenocyt
group
secret
high
level
fig
comparison
cytokin
concentr
secret
splenocyt
immun
mice
show
smqadjuv
formul
induc
significantli
higher
secret
alumadjuv
formul
licensur
ga
vaccin
would
bring
global
public
health
benefit
prevent
number
clinic
manifest
caus
ga
would
lower
diseas
burden
also
reduc
prescript
antibiot
therefor
posit
contribut
fight
antimicrobi
resist
nonm
protein
vaccin
contain
conserv
ga
protein
adi
scpa
slo
spycep
tf
low
sequenc
variat
high
coverag
among
ga
isol
differ
geograph
region
use
alum
adjuv
test
differ
anim
model
variou
result
immun
provid
protect
superfici
skin
infect
model
mice
decreas
sever
pharyng
tonsil
clinic
sign
pharyng
model
nonhuman
primat
hand
formul
fail
provid
protect
use
human
plasminogen
mous
model
invas
lethal
infect
given
human
plasminogen
mous
model
wellestablish
model
evalu
system
ga
dissemin
vaccineinduc
protect
evid
model
purifi
protein
use
antigen
decid
investig
whether
altern
adjuv
could
improv
efficaci
studi
test
six
differ
adjuv
tabl
contain
molecul
immunomodulatori
properti
contain
delta
inulin
plantbas
polysaccharid
shown
enhanc
antibodi
titer
cellular
immun
respons
cpg
agonist
provid
addit
immunostimulatori
properti
addit
delta
inulin
cpg
contain
murabutid
stimul
pattern
recognit
receptor
inulinbas
adjuv
induc
significantli
higher
antibodi
titer
antigen
seen
pbsadjuv
induc
high
antigenspecif
antibodi
titer
howev
rate
surviv
vaccin
mice
significantli
higher
seen
pbsadjuv
control
group
swe
adjuv
squaleneinwat
emuls
composit
swe
adjuv
similar
adjuv
current
use
sever
influenza
vaccin
avail
market
shown
promot
recruit
immun
cell
inject
site
enhanc
antigen
uptak
antigenpres
cell
promot
local
releas
atp
formul
swe
gener
high
antibodi
titer
antigen
show
protect
ga
lethal
challeng
compar
pb
formul
swe
lq
lmq
adjuv
neutral
liposomebas
formul
contain
cholesterol
dopc
proinflammatori
saponin
adjuv
activ
dendrit
cell
dc
promot
secret
cytokin
lmq
also
contain
synthet
tolllik
receptor
agonist
lipid
bacteriumderiv
agonist
shown
synergist
adjuv
effect
combin
saponin
neutral
liposom
carrier
adjuv
includ
mosquirix
rt
malaria
vaccin
shingrix
hzsu
herp
zoster
vaccin
approv
human
use
smq
squaleneinwat
emuls
contain
cholesterol
synthet
adjuv
also
combin
emuls
contain
bacteri
agonist
test
human
part
develop
mosquirix
rt
vaccin
formul
lq
lmq
smq
provid
signific
protect
invas
lethal
ga
infect
surviv
respect
given
common
ingredi
three
adjuv
formul
tabl
hypothes
addit
crucial
protect
ga
invas
challeng
model
given
antibodi
titer
five
protein
predict
protect
differ
adjuv
group
hypothes
cell
immun
may
relev
predictor
protect
model
next
character
immun
respons
phenotyp
induc
one
protect
adjuv
formul
smq
chosen
associ
highest
rate
surviv
ga
challeng
mice
immun
use
studi
signatur
immun
respons
igg
subclass
gener
differ
formul
show
signific
differ
particularli
abil
gener
antigenspecif
overal
immun
gener
combin
respons
morebalanc
ratio
formul
produc
respons
serum
antibodi
gener
three
formul
abl
recogn
bind
antigen
surfac
live
ga
measur
flow
cytometri
howev
sera
abl
promot
opsonophagocytosi
ga
press
issu
ga
vaccin
develop
establish
correl
protect
use
fasttrack
licensur
vaccin
candid
opson
antibodi
long
associ
protect
infect
proteinbas
vaccin
follow
natur
infect
previou
report
opson
antibodi
detect
sera
mice
use
classic
lancefield
wholeblood
indirect
bactericid
assay
present
studi
abl
detect
opson
antibodi
use
standard
assay
discrep
two
assay
detect
opson
antibodi
report
past
technic
complex
classic
lancefield
wholeblood
assay
make
unfeas
use
clinic
trial
assay
may
becom
wide
accept
standard
assay
investig
presenc
opson
antibodi
ga
studi
mice
immun
protect
invas
lethal
challeng
absenc
opson
antibodi
consequ
work
provid
evid
opson
antibodi
correl
protect
paradigm
necessarili
appli
nonm
protein
antigen
find
highlight
one
weak
need
address
road
licensur
ga
vaccin
begin
address
issu
cellular
recal
respons
investig
antigenstimul
splenocyt
immun
mice
splenocyt
mainli
secret
cytokin
indic
signatur
low
level
contrast
splenocyt
secret
wider
varieti
cytokin
includ
cytokin
immun
result
strong
secret
cytokin
suggest
potenti
role
respons
protect
invas
ga
infect
follow
vaccin
previous
report
scpaspecif
respons
may
play
import
role
agerel
immun
ga
follow
natur
exposur
human
observ
line
result
highlight
import
respons
especi
protect
immun
ga
infect
even
though
mous
model
repres
best
preclin
model
mimic
ga
infect
enabl
us
investig
immun
mechan
combat
infect
identifi
protect
vaccin
candid
mous
model
ideal
initi
preclin
test
vaccin
candid
particular
case
human
plasminogen
mous
model
allow
us
investig
effect
differ
adjuv
promot
protect
efficaci
advanc
vaccin
candid
crucial
investig
efficaci
use
morerepres
model
infect
pharyng
model
nonhuman
primat
potenti
experiment
human
challeng
model
develop
pathway
vaccin
test
could
ideal
use
ga
vaccin
candid
order
build
strong
evid
vaccin
efficaci
ga
infect
work
highlight
import
adjuv
select
order
rais
protect
immun
respons
invas
ga
infect
adjuv
provid
balanc
respons
smq
may
requir
optim
protect
provid
ga
vaccin
particular
base
nonm
protein
antigen
recombin
protein
express
escherichia
coli
star
grown
luriabertani
medium
lb
supplement
ampicillin
streptococcu
pyogen
strain
invas
clinic
isol
grown
hors
blood
agar
plate
toddhewitt
broth
supplement
wtvol
yeast
extract
infect
experi
master
frozen
stock
prepar
previous
describ
protein
streptococc
antigen
contain
adi
scpa
slo
spycep
tf
express
e
coli
star
cell
purifi
affin
chromatographi
previous
describ
protein
prepar
subject
filter
steril
final
formul
tag
cleav
antigen
enzymelink
immunosorb
assay
elisa
previous
report
composit
adjuv
use
studi
provid
tabl
aluminum
hydroxid
gel
alhydrogel
alum
purchas
invivogen
ca
usa
adjuv
formul
base
microparticl
delta
inulin
provid
vaxin
pti
ltd
adelaid
australia
swe
lq
lmq
smq
adjuv
formul
manufactur
vaccin
formul
institut
swe
adjuv
squaleneinwat
emuls
prepar
previous
describ
smq
adjuv
prepar
mix
solut
desert
king
intern
ca
usa
pb
squaleneinwat
emuls
contain
cholesterol
mercksigma
usa
synthet
agonist
lipid
also
call
phad
catalog
merckavanti
usa
smq
adjuv
mix
antigen
pb
without
ca
mg
obtain
lq
adjuv
prepar
ad
solut
desert
king
intern
ca
usa
pb
neutral
liposom
prepar
lipid
film
method
use
dopc
cholesterol
lipid
rehydr
dulbecco
phosphatebuff
salin
dpb
ph
without
ca
mg
buffer
follow
extrus
lq
mix
antigen
pb
without
ca
mg
obtain
lmq
adjuv
prepar
way
incorpor
lipid
film
lmq
adjuv
mix
antigen
pb
without
ca
mg
obtain
group
n
femal
male
mice
week
old
heterozyg
human
plasminogen
gene
immun
intramuscularli
day
total
protein
adjuv
adjuv
list
tabl
reach
final
volum
per
dose
negativecontrol
group
immun
pb
combin
correspond
adjuv
purifi
protein
formul
alum
use
posit
control
serum
sampl
taken
immun
day
day
immun
mice
infect
subcutan
ga
infect
dose
confirm
day
infect
enumer
cfu
mice
monitor
twice
daili
day
given
score
base
observ
clinic
sign
see
tabl
supplement
materi
antibodi
bind
opsonophagocyt
kill
splenocyt
stimul
assay
mice
per
group
immun
day
mice
use
neg
control
day
mice
euthan
blood
obtain
via
heart
punctur
spleen
remov
asept
condit
antibodi
titer
individu
antigen
determin
elisa
describ
previous
antigenspecif
mous
igg
antibodi
detect
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
antibodi
calbiochem
dilut
measur
titer
differ
igg
subclass
secondari
hrpgoat
antimous
antibodi
abcam
use
dilut
antibodi
bind
ga
surfac
done
previous
describ
use
ga
strain
goat
antimous
igg
conjug
alexa
fluor
southernbiotech
dilut
use
detect
cell
wash
pb
fix
wtvol
total
event
acquir
use
bd
accuri
flow
cytomet
bd
bioscienc
opsonophagocyt
kill
assay
perform
previous
describ
briefli
ga
strain
wash
dilut
cfuml
opson
buffer
volvol
defin
fetal
bovin
serum
fb
hyclon
wtvol
gelatin
sigmaaldrich
compani
ltd
hank
balanc
salt
solut
camg
mix
sera
serial
dilut
opson
buffer
roundbottom
plate
incub
min
rpm
room
temperatur
volum
babi
rabbit
complement
dilut
one
six
opson
buffer
differenti
human
promyelocyt
leukemia
cell
ad
dilut
sera
multipl
infect
ga
incub
min
shake
rpm
prior
assay
cell
differenti
incub
dimethylformamid
day
dilut
opson
buffer
cellsml
plate
incub
ice
min
well
spot
onto
toddhewitt
yeast
agar
plate
toddhewitt
broth
supplement
wtvol
yeast
extract
wtvol
bacteriolog
agar
overlay
agar
consist
toddhewitt
broth
supplement
wtvol
yeast
extract
wtvol
chlorid
sigmaaldrich
compani
ltd
pour
plate
plate
incub
overnight
number
surviv
cfu
determin
use
autom
coloni
counter
synbiosi
dilut
sera
result
kill
calcul
opson
index
asept
remov
spleen
press
cell
strainer
corn
falcon
obtain
singlecel
suspens
pb
cell
wash
pb
red
blood
cell
subsequ
lyse
use
red
blood
cell
lysi
buffer
roch
cell
resuspend
rpmi
supplement
volvol
fetal
bovin
serum
volvol
splenocyt
cell
stimul
use
antigen
mix
protein
medium
ad
neg
control
unstimul
splenocyt
incub
h
cultur
supernat
isol
centrifug
store
cytokin
quantif
cytokin
secret
cultur
supernat
quantifi
use
legendplex
mous
panel
biolegend
follow
manufactur
protocol
sampl
acquir
use
bd
accuri
flow
cytomet
bd
bioscienc
data
analyz
use
legendplex
data
analysi
softwar
biolegend
concentr
cytokin
due
antigen
stimul
calcul
subtract
concentr
cytokin
unstimul
sampl
concentr
stimul
sampl
antigenspecif
endpoint
titer
analyz
use
twotail
mannwhitney
u
test
p
valu
consid
statist
signific
graphpad
prism
murin
surviv
curv
analyz
use
mantelcox
log
rank
test
p
valu
consid
statist
signific
graphpad
prism
flow
cytometri
data
analyz
use
probabl
bin
algorithm
flowjo
tree
star
inc
cutoff
valu
x
experiment
determin
sampl
x
valu
consid
signific
p
confid
opson
indic
compar
use
kruskalw
test
correct
multipl
comparison
use
dunnett
test
p
valu
consid
statist
signific
graphpad
prism
concentr
cytokin
secret
splenocyt
compar
use
twotail
unpair
test
p
valu
consid
statist
signific
graphpad
prism
anim
procedur
conduct
accord
australian
code
care
use
anim
scientif
purpos
breed
experiment
procedur
use
human
plasminogen
mice
approv
univers
queensland
anim
ethic
committe
